Researchers have tied a small molecule produced by gut bacteria to the buildup of arterial plaque that precedes heart attacks and strokes. Imidazole propionate, or ImP, is a histidine-derived metabolite that appears in higher concentrations in people with coronary artery disease, even after standard risk factors like cholesterol and blood pressure are accounted for. The finding, supported by imaging data, mouse experiments, and prospective human cohorts, raises a pointed question: could blocking ImP’s signaling pathway slow plaque growth in patients whose arteries keep narrowing despite statin therapy?
How a bacterial metabolite ended up linked to coronary plaque
The connection between ImP and heart disease did not emerge overnight. The molecule was first identified as a product of microbial histidine metabolism that impairs insulin signaling through a chain involving p38-gamma, p62 phosphorylation, and mTORC1 activation in type 2 diabetes. That work, published in Cell, established ImP as a bioactive compound with real metabolic consequences, not just a bystander circulating in blood.
Separate research then showed ImP can also interfere with AMPK-related pathways and reduce the effectiveness of metformin, the most widely prescribed diabetes drug worldwide. For people already managing insulin resistance with standard medications, that interference could quietly worsen cardiometabolic risk without any obvious signal on routine lab work.
The leap from metabolic disruption to arterial disease came from studies that combined plasma ImP measurements with coronary imaging. Mastrangelo and colleagues reported that ImP is associated with subclinical atherosclerosis on imaging, including coronary artery calcium scores and PET/MRI-based inflammatory activity in arterial walls. In mouse models, the same group demonstrated that ImP promotes plaque formation through a specific receptor on immune cells: the imidazoline-1 receptor, also known as nischarin, on myeloid cells. When ImP binds that receptor, it activates mTORC1 in those cells, triggering inflammatory cytokine release that accelerates plaque buildup.
A research highlight in Signal Transduction and Targeted Therapy described this mechanistic chain as ImP promoting atherosclerosis through myeloid imidazoline-1 receptor signaling and flagged a compound called AGN192403 as a selective receptor antagonist worth investigating. That detail matters because it names a specific pharmacological target, not just a correlation.
Human data from angiography and prospective cohorts
The case for ImP is not built on animal experiments alone. In patients undergoing cardiac catheterization, higher plasma ImP was associated with greater odds of coronary artery disease after multivariable adjustment, according to work published in Arteriosclerosis, Thrombosis, and Vascular Biology. The same study provided experimental evidence that ImP impairs endothelial function, damaging the lining of blood vessels whose dysfunction is an early step in plaque formation.
In people living with HIV, a population with elevated baseline cardiometabolic risk, researchers combined 16S rRNA gut-microbiome sequencing with liquid chromatography-tandem mass spectrometry measurements of plasma ImP and coronary CT angiography. They found that ImP was higher in those with obstructive disease and that specific gut microbiota alterations tracked with those elevated levels. The study classified patients into obstructive, nonobstructive, and no-disease groups, and ImP distinguished between them even after adjusting for traditional cardiovascular risk factors.
Prospective epidemiological data added a forward-looking dimension. A multi-stage metabolomics study published in PLOS Medicine used discovery, in-silico validation, and targeted validation phases to tie circulating gut microbial metabolites, including ImP, to incident coronary heart disease. That design moves the evidence beyond cross-sectional snapshots and toward the kind of longitudinal risk data clinicians need before changing practice.
Separately, research published in the European Heart Journal evaluated ImP as a predictor of cardiometabolic risk in patients with established coronary artery disease, accounting for other gut-derived markers such as TMAO. The finding that ImP adds predictive information beyond TMAO is significant because TMAO has been the dominant microbial metabolite in cardiovascular research for over a decade, and ImP appears to operate through a distinct biological pathway.
Testing whether blocking the receptor could slow plaque growth
The mechanistic chain from ImP to the imidazoline-1 receptor to mTORC1 activation in myeloid cells to inflammatory cytokine release to plaque formation creates a testable therapeutic hypothesis: selectively blocking the imidazoline-1 receptor should slow coronary plaque growth on serial CT angiography in patients with elevated ImP, independently of LDL lowering. The logic is straightforward. If ImP drives inflammation in the vessel wall, then interrupting its signaling should blunt that inflammatory response, stabilize plaques, or even modestly reduce plaque volume.
Preclinical work suggests several ways to probe this hypothesis. In mouse models prone to atherosclerosis, investigators can compare plaque burden in animals exposed to high ImP levels with and without pharmacologic receptor blockade. Endpoints such as lesion size, necrotic core area, fibrous cap thickness, and inflammatory-cell infiltration would indicate whether antagonizing the receptor truly alters disease biology. Parallel experiments in cultured human macrophages and endothelial cells could clarify how much of the effect is driven by immune activation versus direct endothelial injury.
Translating those findings into humans would likely start with a phase 1 trial of a selective imidazoline-1 receptor antagonist in people with stable coronary artery disease and elevated ImP. Initial goals would focus on safety, tolerability, and pharmacokinetics, along with exploratory biomarkers such as inflammatory cytokines, monocyte activation markers, and changes in endothelial function measured by flow-mediated dilation. If those signals look promising, a phase 2 study could randomize patients already on guideline-directed therapy, including high-intensity statins, to receive the antagonist or placebo and follow them with serial coronary CT angiography over 12 to 24 months.
Crucially, such a trial would need to enrich for individuals in whom the ImP pathway is likely relevant. That might mean selecting patients with persistently high plasma ImP despite optimized lipid control, or those whose plaques show imaging features consistent with inflammation, such as low-attenuation plaque or perivascular fat changes. Stratifying by baseline ImP could also reveal whether the drug’s benefit is confined to those with the highest levels, supporting a precision-medicine approach rather than a one-size-fits-all add-on therapy.
Designers of these trials would have to grapple with several unanswered questions. One is whether lowering ImP itself, through dietary changes, probiotics, or antibiotics that reshape the gut microbiome, might produce similar benefits without directly targeting the receptor. Another is whether chronic receptor blockade could have unintended consequences, given that imidazoline receptors are expressed in multiple tissues and have been implicated in blood pressure regulation and other physiological processes.
Regulatory agencies will also want to see that any incremental reduction in plaque progression translates into meaningful clinical outcomes, such as fewer heart attacks or revascularization procedures. That will require larger, longer trials powered for events, not just imaging surrogates. Yet the history of cardiovascular drug development shows that therapies which substantially slow plaque growth or enhance stability on imaging often do reduce events over time, especially when layered on top of statins and other standard treatments.
For now, ImP remains a biomarker with a compelling mechanistic backstory rather than a validated therapeutic target. But the convergence of microbiome science, metabolomics, vascular biology, and advanced imaging has pushed it to the front of a new wave of research that views atherosclerosis not only as a lipid-storage disease but also as a chronic inflammatory condition shaped by gut-derived signals. If ongoing work confirms that blocking the imidazoline-1 receptor can safely dampen that signal, clinicians may one day have a new tool for patients whose arteries continue to narrow despite doing everything current guidelines recommend.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
